{
    "clinical_study": {
        "@rank": "33343", 
        "arm_group": {
            "arm_group_label": "Flexible Dose Latuda\u00a9", 
            "arm_group_type": "Experimental", 
            "description": "Lurasidone (Latuda\u00a9)dose will be determined solely by the clinician in accordance with the best interests of each participant."
        }, 
        "brief_summary": {
            "textblock": "The overarching purpose of this pilot study is to collect preliminary data regarding the\n      variability of weight gain associated with lurasidone (Latuda\u00a9) treatment of antipsychotic\n      naive children and adolescents in order to inform decisions about including a lurasidone arm\n      in a future large scale trial of different approaches to minimize antipsychotic associated\n      weight gain in the pediatric population. In adults, lurasidone appears to cause minimal\n      weight gain. The participants will be 6-19 years old with psychotic spectrum, mood spectrum,\n      or autism spectrum disorders. They will have 4 weeks or less of lifetime antipsychotic\n      exposure."
        }, 
        "brief_title": "Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizoaffective Disorder", 
            "Schizophreniform Disorder", 
            "Psychosis NOS", 
            "Autistic Disorder", 
            "Asperger Syndrome", 
            "Child Development Disorders, Pervasive", 
            "Bipolar I Disorder", 
            "Bipolar II Disorder", 
            "Mood Disorder NOS", 
            "Severe Major Depression With Psychotic Features", 
            "Single Episode Major Depression Without Psychotic Symptoms", 
            "Severe Mood Disorder With Psychotic Features"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Developmental Disabilities", 
                "Child Development Disorders, Pervasive", 
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major", 
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Schizophrenia", 
                "Asperger Syndrome", 
                "Bipolar Disorder", 
                "Mood Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-site, 12-week, open-label study assessing the weight and metabolic changes\n      associated with lurasidone treatment. Antipsychotic naive subjects will start open-label\n      treatment by following a flexible titration schedule. Quasi-antipsychotic naive subjects\n      (less than 4 weeks of total AP treatment) will be started on lurasidone and tapered off the\n      other antipsychotic over an estimated 4 weeks depending on the dose and tolerability of the\n      prior antipsychotic. Other psychoactive medications including antidepressants,\n      benzodiazepines, stimulants, alpha-2 agonists, and mood stabilizers are allowed as long as\n      the dose is not changed, unless it is clinically necessary. Assessments of weight, efficacy,\n      and side effects are conducted at baseline, week 2, week 4, week 8, and week 12. The primary\n      outcome is percent change in weight. The secondary outcomes include psychiatric efficacy\n      measures and side effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female children and adolescents between 6 and 19 years of age of any race or\n             ethnicity\n\n          -  Subject must meet DSM-IV-TR criteria for a psychotic spectrum, mood spectrum or\n             autism spectrum disorder as defined by one of the following diagnoses:\n\n               -  schizophrenia (any type)\n\n               -  schizoaffective disorder\n\n               -  schizophreniform disorder\n\n               -  psychosis NOS\n\n               -  autistic disorder with significant irritability/aggression (ABC-C  Irritability\n                  subscale score of greater than or equal to 18)\n\n               -  Asperger syndrome with significant irritability/aggression (ABC-C  Irritability\n                  subscale score of greater than or equal to 18)\n\n               -  pervasive developmental disorder NOS with significant irritability/aggression\n                  (ABC-C  Irritability subscale score of greater than or equal to 18)\n\n               -  bipolar type I\n\n               -  bipolar type II\n\n               -  mood disorder NOS\n\n               -  major depression with psychotic features\n\n               -  major depression (unresponsive to 2 different antidepressants)\n\n               -  severe mood dysregulation (SMD) according to Leibenluft and colleagues broad\n                  spectrum bipolar disorder\n\n          -  Subjects must have \u2264 4 weeks of lifetime exposure to an antipsychotic medication at\n             any dosage. These medications include olanzapine (Zyprexa\u00a9), quetiapine (Seroquel\u00a9),\n             risperidone (Risperdal\u00a9), ziprasidone (Geodon\u00a9), aripiprazole (Abilify\u00a9), asenapine\n             (Saphris\u00a9), iloperidone (Fanapt\u00a9), lurasidone (Latuda\u00a9), haloperidol, chlorpromazine,\n             perphenazine, fluphenazine, thiothixene, or clozapine\n\n          -  Subjects on other psychoactive medications are asked not to change dose of those\n             medications during the course of the study unless clinically necessary\n\n          -  Sexually active girls must agree to use two effective forms of birth control (i.e.\n             hormonal or spermicidal and barrier) or be abstinent)\n\n          -  Primary caretaker is able to participate in study appointments as is clinically\n             indicated\n\n          -  Ability of child to participate in all aspects of the protocol per investigator's\n             clinical judgment\n\n          -  After considering all aspects of study participation the subject (if an adult) or\n             subject's parent or LAR must consent to participation\n\n          -  After considering all aspects of study participation, the subject must assent to\n             participation if it is developmentally appropriate to obtain assent\n\n        Exclusion Criteria:\n\n          -  Based on current or lifetime DSM-IV-TR criteria, a diagnosis of Eating Disorder\n             (Anorexia Nervosa or Bulimia Nervosa)\n\n          -  Based on DSM-IV-TR criteria, a diagnosis of Substance Dependence Disorder (other than\n             tobacco dependence) within the past month\n\n          -  Treatment with the following concomitant medications: strong CYP3A4 inhibitors (ex:\n             Ketoconazole), strong CYP3A4 inducers (ex: Rifampin)\n\n          -  Current or past treatment with lurasidone (Latuda\u00a9) that resulted in a non-response\n             or intolerance\n\n          -  Females who are pregnant or breast-feeding\n\n          -  Ongoing or previously undisclosed child abuse requiring new department of social\n             service intervention\n\n          -  Subjects who, in the Investigator's opinion, might not be suitable for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "19 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731119", 
            "org_study_id": "12-2302"
        }, 
        "intervention": {
            "arm_group_label": "Flexible Dose Latuda\u00a9", 
            "description": "All subjects will be started on 20-40mg of Latuda\u00a9 at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.", 
            "intervention_name": "Latuda\u00a9", 
            "intervention_type": "Drug", 
            "other_name": "Lurasidone Hydrochloride tablets"
        }, 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Latuda,lurasidone,antipsychotics,autism, mood, psychosis", 
        "lastchanged_date": "February 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "University of Maryland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glen Oaks", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11004"
                    }, 
                    "name": "The Zucker Hillside Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27517"
                    }, 
                    "name": "University of North Carolina"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents", 
        "overall_official": [
            {
                "affiliation": "University of North Carolina, Chapel Hill", 
                "last_name": "Linmarie Sikich, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Johns Hopkins University", 
                "last_name": "Mark Riddle, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Zucker Hillside Hospital", 
                "last_name": "Christoph Correll, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Maryland", 
                "last_name": "Gloria Reeves, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent change in weight from Baseline to Week 12 will be assessed as the primary outcome measure. Subjects will be asked to step on a special scale called a TANITA which will calculate  weight, fat mass at each study visit.", 
            "measure": "Change in Weight", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731119"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of North Carolina, Chapel Hill", 
            "investigator_full_name": "Linmarie Sikich, MD", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Data will be collected on why participants terminated the study. If terminated early, the specific reason will be collected such as efficacy or tolerability.", 
                "measure": "Proportion of Participants Completing Treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Efficacy measures including the Brief Psychiatric Rating Scale (BPRS-C) which measures symptomatology on five subscales including depression/anxiety, psychomotor excitation/mania, behavior problems, thinking disturbance, and organicity and the Aberrant Behavior Checklist-Community (ABC-C) which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and social withdrawal.", 
                "measure": "Changes in Efficacy Measures", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Assessment of the medication side effects associated with lurasidone (Latuda\u00a9) in children and adolescents.", 
                "measure": "Side Effects", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Overall psychiatric functioning will be assessed with the severity (CGI-S) and improvement (CGI-I) subscales of the CGI. CGI-S items are rated from 1 (normal, not ill) to 7 (very severely ill). CGI-I items are rated from 1 (very much improved) to 7 (very much worse).", 
                "measure": "Overall Clinical Improvement", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Foundation of Hope, North Carolina", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Maryland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Zucker Hillside Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}